16 news items
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
ALT
AXTI
HRBR
17 Jun 24
agonists targeting weight-loss. Pemvidutide's ability to compete with other GLP-1 agonists targeting weight-loss was particularly important
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
ALT
AXTI
EQIX
7 Jun 24
agonists targeting weight-loss. Pemvidutide's ability to compete with other GLP-1 agonists targeting weight-loss was particularly important to analysts
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, and Li Auto and Encourages Investors to Contact the Firm
AXTI
INTC
LI
30 May 24
of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power, and then will look to expand
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, and Li Auto and Encourages Investors to Contact the Firm
AXTI
INTC
LI
26 May 24
of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power, and then will look to expand
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, and Li Auto and Encourages Investors to Contact the Firm
AXTI
INTC
LI
22 May 24
phase of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power, and then will look to expand
fk77w 5d1fa9
AXTI
INTC
LI
18 May 24
that it will revert to the validation phase of sales by shifting its focus toward its core user group, target sales to cities with stronger purchasing power
r8ya2e7whuqco6y7r11 tsooyew8iw9cj
AXTI
3 May 24
0
Analysts have set 12-month price targets for AXT, revealing an average target of $5.11, a high estimate of $6.00
rp7jb631bywnkpxm5i08hg7dra4ppn357i4souktd70cf9j8vi8p4axtansn
AXTI
3 May 24
Wedbush analyst Matt Bryson reiterates AXT (NASDAQ:AXTI) with a Outperform and maintains $6 price target.
vcn04yfmy42js9eje1lxn79q0snc 27tiqmv6sh1g3c
AXTI
3 May 24
Needham analyst Charles Shi reiterates AXT (NASDAQ:AXTI) with a Buy and maintains $5 price target.
1ho p2ynjcun6uq5k
AXTI
9 Apr 24
Craig-Hallum analyst Richard Shannon maintains AXT (NASDAQ:AXTI) with a Buy and raises the price target from $3.75 to $5.
wsrd9qx4ic 1reehmv7r1a7w1uwyej7syk2eoqm22
AXTI
9 Apr 24
Needham analyst Charles Shi reiterates AXT (NASDAQ:AXTI) with a Buy and maintains $5 price target.
ezwwyjlede6fb8ijlg l7arbdx
AEHL
AGEN
AIRC
8 Apr 24
Thibault initiated coverage on Outset Medical with a Buy rating and announced a price target of $6.
Dogness (International
nqvhob54nab6pf0 3zqxuc5i6jvafwo37x23flumy6eajoprh
AXTI
8 Apr 24
Wedbush analyst Matt Bryson maintains AXT (NASDAQ:AXTI) with a Outperform and maintains $6 price target.
e1bb7juwd91gtf9d55luzdvg628iep542vwy0fyty xc5dn8epr46
AXTI
5 Apr 24
of 12-month price targets, revealing an average target of $4.81, a high estimate of $6.00, and a low estimate of $3.75. Observing a 70.57% increase
c6ml9o7icv3y6of5lm63j47qjot8cy6ij6otnjox3
AXTI
5 Apr 24
B. Riley Securities analyst Dave Kang maintains AXT (NASDAQ:AXTI) with a Buy and raises the price target from $3.8 to $5.5.
egqaprisapioki w1f9z5h0qu0kr7vd5tu2
ABIO
ACHL
ADXN
4 Apr 24
with a Buy rating and announced a $5 price target.
Tevogen Bio Holdings Inc
- Prev
- 1
- Next